Correspondence 0001493152-24-024766 from FibroBiologics, Inc. (FBLG)

FibroBiologics, Inc.
Date: June 21, 2024 · CIK: 0001958777 · Accession: 0001493152-24-024766

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-280303

Date

June 21, 2024

Author

Chief

Form

CORRESP

Company

FibroBiologics, Inc.

Letter

VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Attention: Doris Stacey Gama RE: FibroBiologics, Inc. (the “Company”) Registration Statement on Form S-1 File No. 333-280303

Dear Mrs. Gama:

Pursuant to Rule 461(a) under the Securities Act of 1933, as amended, the Company hereby respectfully requests that the effective date of the Company’s Registration Statement on Form S-1 (File No. 333-280303) be accelerated by the Securities and Exchange Commission to 5:00 p.m. Washington D.C. time on June 25, 2024, or as soon as practicable thereafter, unless the Company notifies you otherwise prior to such time.

We request that we be notified of such effectiveness by a telephone call to Brian Fenske at (713) 651-5557 or Lee McIntyre at (713) 651-5328 of Norton Rose Fulbright (US) LLP, and that such effectiveness also be confirmed in writing.

Very
truly yours,
FibroBiologics,
Inc.

Show Raw Text

CORRESP
1
filename1.htm

FIBROBIOLOGICS,
INC.

455
E. Medical Center Blvd.

Suite
300

Houston,
Texas 77598

June
21, 2024

VIA
EDGAR

Securities
and Exchange Commission

Division
of Corporation Finance

Office
of Life Sciences

100
F Street, N.E.

Washington,
D.C. 20549

    Attention:
    Doris
    Stacey Gama

    RE:
    FibroBiologics,
    Inc. (the “Company”)

    Registration
    Statement on Form S-1

    File
    No. 333-280303

Dear
Mrs. Gama:

Pursuant
to Rule 461(a) under the Securities Act of 1933, as amended, the Company hereby respectfully requests that the effective date of the
Company’s Registration Statement on Form S-1 (File No. 333-280303) be accelerated by the Securities and Exchange Commission to
5:00 p.m. Washington D.C. time on June 25, 2024, or as soon as practicable thereafter, unless the Company notifies you otherwise prior
to such time.

We
request that we be notified of such effectiveness by a telephone call to Brian Fenske at (713) 651-5557 or Lee McIntyre at (713) 651-5328
of Norton Rose Fulbright (US) LLP, and that such effectiveness also be confirmed in writing.

    Very
    truly yours,

    FibroBiologics,
    Inc.

    By:
    /s/
    Mark Andersen

    Name:

    Mark
    Andersen

    Title:

    Chief
    Financial Officer

SecProbe.io